CEL-SCI Corporation is dedicated to advancing immunotherapy research and development for cancer and infectious diseases. The company's flagship investigational immunotherapy, Multikine, is currently undergoing a Phase III clinical trial aimed at treating head and neck cancer. In addition to this, CEL-SCI is pioneering the Ligand Epitope Antigen Presentation System (LEAPS), a patented pre-clinical process designed for T-cell modulation, which encourages the human immune system to combat infections caused by bacteria, viruses, and parasites. LEAPS also holds promise for treating autoimmune diseases, allergies, transplantation rejections, and cancer itself. Furthermore, the company is developing LEAPS-H1N1-DC and product candidates CEL-2000 and CEL-4000 to address rheumatoid arthritis, alongside LEAPS COV-19, focused on COVID-19 treatment. CEL-SCI maintains a collaborative agreement with the University of Georgia's Center for Vaccines and Immunology to further develop the LEAPS COVID-19 immunotherapy. The cost of revenue for the company is $3,969,183.00 showcasing its production and operational expenses. In terms of operational overhead, the company reported selling, general, and administrative expenses of $4,221,840.00. The total operating expenses amount to $22,383,291.00 which encompasses various costs incurred during operations. The earnings per share (EPS) is reported at -$13.50 indicating the company's profitability on a per-share basis. Additionally, the weighted average number of shares outstanding is 1,988,651.00 highlighting the company's shareholder base. In the current market scene, CEL-SCI Corporation's stock is considered affordable at $3.63 making it an attractive option for budget-conscious investors. The stock demonstrates an average trading volume of 830,741.00 suggesting a moderate level of liquidity, which can be beneficial for investors looking to buy or sell. With a market capitalization of $71,780,929.00 the company falls into the small-cap category within the stock market. As a key player in the Biotechnology industry, CEL-SCI contributes substantially to the overarching market landscape by driving innovation and research. Furthermore, it belongs to the Healthcare sector, which is pivotal in fostering growth and advancements in healthcare and therapeutic solutions.